基于深度学习CT分类器与病理标志物增强II期结直肠癌风险分层以优化辅助治疗决策
研究纳入12个中心2992例II期结直肠癌患者,开发深度学习CT分类器STAR-CRC并联合病理标志物构建IRIS-CRC风险分层系统。外部验证中IRIS-CRC较指南分层系统将27.1%高危患者降为有利组、6.5%低危患者升为极差预后组,在中间危组中重分类40.1%为有利预后、7.0%为极差预后。IRIS-CRC提供更精准的个体化风险评估,可能避免低危患者不必要的辅助化疗并识别需更积极治疗的高危个体。
要点
- IRIS-CRC将II期结直肠癌分为四个预后组,3年无病生存率分别为≥95%、95%-75%、75%-55%、≤55%。
- 外部验证中IRIS-CRC较GRSS-CRC将27.1%高危患者降为有利组、6.5%低危患者升为极差预后组。
- GRSS-CRC中间危组中IRIS-CRC重分类40.1%为有利预后、7.0%为极差预后。
核心结论
- IRIS-CRC较当前指南危险因素提供更精准的个体化风险评估,可能避免低危患者不必要的辅助化疗并识别需更积极治疗的高危个体。
研究设计与样本
- 研究分析来自12个中心的2992例II期结直肠癌患者。
- 使用1587例患者的多平面CT图像开发深度学习分类器STAR-CRC(训练:内部验证=7:3),并在8个独立中心的1405例患者中验证。
- 基于病理标志物(pT4分期、淋巴结检出数、神经周围侵犯、淋巴血管侵犯)的复合评分用于细化不确定风险组,形成IRIS-CRC。
主要发现
- IRIS-CRC将患者分为四个预后组,3年无病生存率分别为≥95%、95%-75%、75%-55%、≤55%。
- 外部验证中,与GRSS-CRC相比,IRIS-CRC将27.1%的高危患者降为有利组,将6.5%的低危患者升为极差预后组。
- 外部验证数据集的GRSS-CRC中间危组中,IRIS-CRC将40.1%重分类为有利预后、7.0%为极差预后。
- IRIS-CRC在化疗和非化疗队列中均保持泛化性。
关键数值与推荐
- IRIS-CRC分层后的3年无病生存率四组分别为≥95%、95%-75%、75%-55%、≤55%。
- 外部验证中IRIS-CRC较GRSS-CRC降级27.1%高危患者至有利组、升级6.5%低危患者至极差预后组。
- GRSS-CRC中间危组中IRIS-CRC重分类40.1%为有利预后、7.0%为极差预后。
临床怎么用
- 作者认为IRIS-CRC可能避免低危患者接受不必要的辅助化疗,并识别需更积极治疗的高危个体。
- 作者认为这一新方法有望改善II期结直肠癌的临床决策和结局。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Current risk stratification for stage II colorectal cancer (CRC) has limited accuracy in identifying patients who would benefit from adjuvant chemotherapy, leading to potential overtreatment or undertreatment. We aimed to develop a more precise risk stratification system by integrating artificial intelligence-based imaging analysis with pathological markers. PATIENTS AND METHODS: We analyzed 2992 stage II CRC patients from 12 centers. A deep learning classifier (Swin Transformer Assisted Risk-stratification for CRC, STAR-CRC) was developed using multi-planar computed tomography (CT) images from 1587 patients (training : internal validation = 7 : 3) and validated in 1405 patients from eight independent centers, which stratified patients into low-, uncertain-, and high-risk groups. To further refine the uncertain-risk group, a composite score based on pathological markers (pT4 stage, number of lymph nodes sampled, perineural invasion, and lymphovascular invasion) was applied, forming the Intelligent Risk Integration System for stage II Colorectal Cancer (IRIS-CRC). IRIS-CRC was compared against the guideline-based risk stratification system (GRSS-CRC) for prediction performance and validated in the validation dataset. RESULTS: IRIS-CRC stratified patients into four prognostic groups with distinct 3-year disease-free survival rates (≥95%, 95%-75%, 75%-55%, ≤55%). Upon external validation, compared with GRSS-CRC, IRIS-CRC downstaged 27.1% of high-risk patients into the favorable group, and upstaged 6.5% of low-risk patients into the very poor prognosis group who might require more aggressive treatment. In the GRSS-CRC intermediate-risk group of the external validation dataset, IRIS-CRC reclassified 40.1% as favorable prognosis and 7.0% as very poor prognosis. IRIS-CRC's performance maintained generalizability in both chemotherapy and non-chemotherapy cohorts. CONCLUSIONS: IRIS-CRC offers a more precise and personalized risk assessment than current guideline-based risk factors, potentially sparing low-risk patients from unnecessary adjuvant chemotherapy while identifying high-risk individuals for more aggressive treatment. This novel approach holds promise for improving clinical decision-making and outcomes in stage II CRC.
引用
- Huang YQ, Chen XB, Cui YF, et al. Enhanced risk stratification for stage II colorectal cancer using deep learning-based CT classifier and pathological markers to optimize adjuvant therapy decision. Ann Oncol. 2025. PMID: 40480552. doi:10.1016/j.annonc.2025.05.537
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。